A single arm phase II study of Adjuvant Endocrine therapy, subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT) (DF/HCC 20-347)
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.
The study drugs involved in this study are:
- A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO)
- Hormonal (endocrine) Treatment
Principal Investigator(s)
Steve Lo, MD
Sponsor(s)
Dana-Farber Cancer Institute
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879
Stamford, CT 06902
Main: 203-358-8879